Following science to fruition, putting patients first: An ASCO25 conversation with AstraZeneca

At this year's American Society of Clinical Oncology’s Annual Meeting, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial evaluating first-line treatment in patients with HER2-positive metastatic breast cancer.

Onsite at the Congress in Chicago, web editor Nicole Raleigh spoke with Alison Dziarmaga, VP, US franchise head, breast cancer, at AstraZeneca, about the data, as well as the meeting’s highlights and key takeaways when it comes to future oncological landscape.

Watch this and other conversations from ASCO 2025 here.